Castle Biosciences, Inc. (CSTL) Stock

Castle Biosciences, Inc. is a leading diagnostics company specializing in providing advanced testing services for dermatological cancers. At its core, Castle Biosciences focuses on delivering diagnostic and prognostic solutions that enhance treatment decisions for patients facing skin cancer diagnoses. The company's flagship product, DecisionDx-Melanoma, is a sophisticated multi-gene expression profile (GEP) test designed to accurately assess the risk of metastasis in individuals diagnosed with invasive cutaneous melanoma.

In addition to DecisionDx-Melanoma, Castle Biosciences offers a range of innovative diagnostic tests tailored to different types of skin cancers. Notably, DecisionDx-UM is a proprietary GEP test specifically developed to predict metastatic risk in patients with uveal melanoma, a rare and challenging form of eye cancer. The company also provides DecisionDx-SCC, a 40-gene expression profile test that leverages tumor biology to predict the likelihood of metastasis in patients with squamous cell carcinoma, particularly those with heightened risk factors.

Furthermore, Castle Biosciences expands its diagnostic cappabilities with DecisionDx DiffDx-Melanoma and myPath Melanoma tests. These proprietary GEP tests are instrumental in accurately diagnosing suspicious pigmented lesions, enabling precise and timely treatment decisions for patients and their healthcare providers. Through partnerships with physicians, Castle Biosciences delivers these cutting-edge diagnostic services, supporting personalized care approaches.

Established in 2007 and headquartered in Friendswood, Texas, Castle Biosciences continues to advance the field of dermatological oncology with its innovative testing platforms. With a steadfast commitment to improving patient outcomes through advanced diagnostics, the company remains dedicated to addressing critical unmet needs in cancer care, particularly in the realm of skin cancers.